Ocular Therapeutix™ Receives FDA Agreement Under Special Protocol Assessment (SPA) for Registrational Trial of AXPAXLI™ in NPDR

"At least half of all diabetic patients are expected to develop some form of diabetic retinopathy in their lifetime," added David M. Brown, MD, Chief Medical Officer of Retina Consultants of America (RCA). "With 6.4 million Americans currently living with NPDR alone, the disease burden is staggering, yet fewer than 1% of these patients are treated. This unfortunate dynamic is despite the proven efficacy of anti-VEGFs and is driven primarily by the challenges of ongoing intraocular injections in an asymptoma ...